The Prostate · 2025
The 31st Annual Prostate Cancer Foundation Scientific Retreat Report.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miyahira Andrea K, Soule Howard R
Аннотация
BACKGROUND: The 31st Annual Prostate Cancer Foundation (PCF) Scientific Retreat took place in Carlsbad, CA on October 24-26, 2024.
METHODS: The Annual PCF Scientific Retreat is the foremost international conference focused on emerging and cutting-edge basic, translational, and clinical prostate cancer research, as well as research from related disciplines with strong potential to advance prostate cancer understanding and improve patient outcomes.
RESULTS: The 2024 PCF Retreat featured research from many disciplines, including: (i) tumor metabolism; (ii) genomics of prostate cancer racial disparities; (iii) reprogramming macrophages in the tumor immune microenvironment; (iv) high impact clinical trials for patients with prostate cancer; (v) artificial intelligence (AI) in driving innovation in cancer research and cancer care; (vi) lessons from 20 years of STAMPEDE; (vii) the PCF-Veterans Administration (VA) partnership's impact in bringing precision medicine to Veterans; (viii) germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer; (ix) next generation theranostics; (x) emerging immunotherapies; (xi) advanced molecular biology of lethal prostate cancer; (xii) posttranscriptional gene regulation in prostate cancer; (xiii) new biotechnologies in genomic medicine; (xiv) advances in "in vivo" cell therapy platforms and novel small molecule cancer therapies; and (xv) an announcement on the PCF Gender Equity Networking Initiative.
CONCLUSIONS: This report highlights key presentations from the 2024 PCF Scientific Retreat, with the aim of enhancing understanding of ongoing and emerging research, driving future progress in prostate cancer science and patient care, and inspiring broader public support for cancer research.
METHODS: The Annual PCF Scientific Retreat is the foremost international conference focused on emerging and cutting-edge basic, translational, and clinical prostate cancer research, as well as research from related disciplines with strong potential to advance prostate cancer understanding and improve patient outcomes.
RESULTS: The 2024 PCF Retreat featured research from many disciplines, including: (i) tumor metabolism; (ii) genomics of prostate cancer racial disparities; (iii) reprogramming macrophages in the tumor immune microenvironment; (iv) high impact clinical trials for patients with prostate cancer; (v) artificial intelligence (AI) in driving innovation in cancer research and cancer care; (vi) lessons from 20 years of STAMPEDE; (vii) the PCF-Veterans Administration (VA) partnership's impact in bringing precision medicine to Veterans; (viii) germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer; (ix) next generation theranostics; (x) emerging immunotherapies; (xi) advanced molecular biology of lethal prostate cancer; (xii) posttranscriptional gene regulation in prostate cancer; (xiii) new biotechnologies in genomic medicine; (xiv) advances in "in vivo" cell therapy platforms and novel small molecule cancer therapies; and (xv) an announcement on the PCF Gender Equity Networking Initiative.
CONCLUSIONS: This report highlights key presentations from the 2024 PCF Scientific Retreat, with the aim of enhancing understanding of ongoing and emerging research, driving future progress in prostate cancer science and patient care, and inspiring broader public support for cancer research.